Press Releases - OBiO Tech, Inc

Press Releases

Home > Insights > Press Releases >

Press Releases

From Overexpression to CRISPR Screens: Case Studies and Strategy Selection for Lentiviral Vector Based Organoid Engineering

See how lentiviral vectors power organoid research: prostate cancer modeling, colorectal tumor immunology, gastric CRISPR screening, APOA1 overexpression, RBM4 knockdown, USP20 knockout, and more.

Lentiviral Transduction of Organoids: 4 Strategies to Improve Efficiency

Learn 4 practical strategies to overcome organoid lentiviral transduction barriers—dissociation, MOI titration, microinjection/pseudotyping, and repeated transduction—for efficient gene delivery.

Why Lentiviral Vectors Are Widely Used for Organoid Gene Delivery

Explore how lentiviral vectors enable organoid gene overexpression, knockdown, CRISPR editing, labeling, and lineage tracing for disease modeling, drug discovery, and precision medicine.

[On-Target] AAV Infection of the Inner Ear - Serotypes, Promoters & Dosages: All You Need in One Guide!

AAV-mediated gene therapy is a promising strategy for hereditary and acquired hearing loss. This article summarizes key AAV serotypes (e.g., AAV-ie, AAV-GC11), cell-type-specific promoters, and delivery routes for efficient and precise gene delivery to inner ear cells.

AAV-LungX: Non-Invasive Intravenous Delivery with Specific Tropism for Pulmonary Endothelial Cells

Pulmonary endothelial cells (PECs) are critical for lung function and disease. AAV-LungX, a novel AAV vector from OBiO’s AAVneO® platform, enables specific pulmonary endothelial targeting via intravenous injection with minimal liver accumulation (reducing hepatotoxicity). It is used to study pulmonary diseases (e.g., COPD, pulmonary fibrosis, PAH, ARDS), advancing lung gene therapy and research by regulating endothelial dysfunction and inflammation.

© OBiO Tech, Inc. All Rights Reserved